GlassScriptPhysician profile
Thomas J Kayal
NPI 1316081268
$27,296.01
in general payments reported to CMS, 2019-2025
28 companies · $268 in 2025
The $268 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $223 · 2021: $196 · 2022: $259 · 2023: $422 · 2024: $706 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,010 · Travel and Lodging: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,009.96 |
| Travel and Lodging | $385.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $24,845.66 | 2019-2023 | Da Vinci Surgical System |
| Thd America, INC. | $564.59 | 2019-2024 | |
| Ethicon US, LLC | $340.90 | 2019-2024 | Echelon; Endopath, Vistaseal, Harmonic |
| Baxter Healthcare | $221.17 | 2019-2023 | Floseal |
| Acera Surgical, INC. | $193.46 | 2024-2025 | Restrata Wound Matrix |
| Allergan, INC. | $125.26 | 2019-2022 | |
| Stryker Corporation | $115.26 | 2024 | 1788 |
| Abbvie INC. | $110.73 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.78 | 2019 | |
| Integra Lifesciences Corporation | $84.44 | 2021-2023 | Integra, Surgimend, Integra Dermal Regeneration Template |
| Pacira Pharmaceuticals Incorporated | $75.15 | 2019-2024 | Exparel, Iovera |
| Davol INC. | $69.16 | 2021-2025 | Phasix Mesh |
| Vertex Pharmaceuticals Incorporated | $66.69 | 2024-2025 | |
| Endologix LLC | $55.58 | 2021 | |
| Smith+Nephew, INC. | $50.95 | 2023 | Pico 7, Grafix Pl, Oasis |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $30.00 | 2019-2020 | |
| Shire North American Group INC | $28.55 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.31 | 2019-2020 | |
| Medtronic, INC. | $27.68 | 2021-2022 | |
| Misonix INC | $25.41 | 2019 | |
| Baudax Bio INC. | $24.02 | 2022 | |
| Organogenesis INC. | $22.79 | 2019 | |
| Acell, INC. | $18.69 | 2019 | |
| Kci USA, INC. | $18.56 | 2022 | |
| Tela Bio, INC. | $15.39 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Kerecis Limited | $14.46 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Terumo Medical Corporation | $12.71 | 2021 | |
| Cook Medical LLC | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kayal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.